Alternatives to Immunes

Data-driven drug discovery and development company using machine learning and high-throughput biology.

Mapping and reprogramming the immune system with single-cell biology and AI for therapeutic discovery.

AI-powered platform to predict and prevent adverse drug reactions, reducing hospitalizations.

Leveraging the adaptive immune system to diagnose and treat disease.

Develops a computational model of the human body for drug discovery and development.

AI-driven drug discovery platform accelerating breakthrough scientific research.

Clinical-stage biotech developing a monoclonal antibody targeting TSLP for inflammatory diseases.

Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.

Clinical-stage biopharmaceutical company leveraging a proprietary platform to discover and develop novel precision medicines from fungi.

Caris Life Sciences is a leading innovator in molecular science, offering precision medicine solutions for cancer patients through advanced molecular profiling.

AI-powered platform for predicting drug efficacy and safety, reducing clinical trial failures.

AI-powered platform connecting cancer patients to advanced treatments and clinical trials.

AI-powered patient-centric drug simulations to accelerate and de-risk drug development.

Guardant Health is a precision oncology company that develops and commercializes liquid biopsy tests for cancer detection, recurrence monitoring, and treatment selection.

Digital therapeutics platform enhancing drug efficacy and safety through personalized software.

A clinical-stage biopharmaceutical company developing novel immunotherapies.

Clinical-stage biotechnology company developing multi-mechanistic oncolytic immunotherapy programs for cancer treatment.

Develops a platform for adaptive clinical trial design and closed-loop execution.

Oncometra is developing an AI-powered platform to accelerate drug discovery and development for oncology.

Biotechnology company developing immuno-neurology therapies for neurodegenerative diseases.